Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Leerink Partners Maintains Outperform on Travere Therapeutics, Lowers Price Target to $67
Canaccord Genuity Maintains Buy on Travere Therapeutics, Raises Price Target to $72
Guggenheim Maintains Buy on Travere Therapeutics, Lowers Price Target to $78
Travere Crashed Into Its 200-Day Line And Then Reversed Higher; Here's Why
Travere Therapeutics to Participate at Upcoming Investor Conferences
Travere Therapeutics, Inc. Q3 2026 Earnings Call Summary
Why Travere Therapeutics (TVTX) Could Be 34% Undervalued On Its Q3 Loss
Travere Therapeutics (TVTX) Stock Looks Fully Priced After Its 7x Run
What Could Travere Therapeutics (TVTX) New Biomarker Data Mean For IgA Nephropathy?
Travere (TVTX) Q3 2026 Earnings Call Transcript
Travere: Q3 Earnings Snapshot
What Travere Therapeutics (TVTX) Said on Its Q3 Earnings Call
Travere Therapeutics, Inc. (TVTX) Q3 2026 Earnings Call Transcript
Travere Therapeutics (NASDAQ:TVTX) Revenue Beat Offset by Wider-Than-Expected Loss
Here's What Key Metrics Tell Us About Travere (TVTX) Q3 Earnings
Travere Therapeutics Reports Third Quarter 2026 Financial Results
Travere Therapeutics Q3 2026 Earnings Call Transcript
Travere Therapeutics Q3 Adj. EPS $(0.31) Misses $(0.06) Estimate, Sales $224.563M Beat $195.292M Estimate
Travere Therapeutics to Report Third Quarter 2026 Financial Results
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.